Immunordic ApS: Financial statements 2025
CVR: 43773070
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Immunordic ApS (CVR 43773070) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 2,352,263 and a net result of DKK -292,800 compared with DKK 7,762 the year before. That is an increase of 146.1% compared with the year before. Equity in the 2025 report amounted to DKK 606,284. The solvency ratio was 10.2%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 2,352,263
- Profit/Loss
- DKK -292,800
- Equity
- DKK 606,284
- Total Assets
- DKK 5,933,243
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 2.4 mio. | -293 t. | 606 t. | 5 |
| 2024 | - | 956 t. | 8 t. | 899 t. | 3 |
| 2023 | - | 541 t. | -49 t. | -9 t. | 2 |
Official annual report
How creditworthy is Immunordic ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Immunordic ApS has published its annual report for 2024. Gross profit came to DKK 955,745, and the net result was DKK 7,762.
About Immunordic ApS
Immunordic ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Synobody ApS. The management consists of Emil Arvedsen and Jannik Faliu. The company is owned by Arvedsen & Faliu Holding ApS. According to the 2025 annual report, the company had an average of 5 employees. In 2025, the company reported a gross profit of DKK 2,352,263 and a net result of DKK -292,800 compared with DKK 7,762 the year before. Equity in the 2025 report amounted to DKK 606,284.